Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rosuvastatin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    106 result(s) found for: Rosuvastatin. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2008-002332-15 Sponsor Protocol Number: D1840M00006 Start Date*: 2008-09-15
    Sponsor Name:AstraZeneca AB
    Full Title: A randomised, double-blind, placebo-controlled study to evaluate the transthoracic Doppler echocardiography method as a non-invasive method for coronary function measurements; ability to detect sho...
    Medical condition: In this study the IMP, rosuvastatin, is used as a tool compound for creating favourable lipid-altering, anti-inflammatory or other pleiotropic effects which are believed to change coronary flow res...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004556-30 Sponsor Protocol Number: LPS15021 Start Date*: 2018-08-24
    Sponsor Name:Sanofi-Aventis Groupe
    Full Title: A Multicenter, Randomized, Double-blind, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of a New Formulation of Zenon (Ezetimibe/Rosuvastatin Fixed Dose Combination) in Patien...
    Medical condition: Patients with Primary Hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002333-11 Sponsor Protocol Number: R727-CL-1118 Start Date*: 2013-04-12
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind Study of the Efficacy and Safety of REGN727 Added-on to Rosuvastatin versus Ezetimibe Added-on to Rosuvastatin versus Rosuvastatin Dose Increase in Patients Who are Not C...
    Medical condition: Patients with Non-familial hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH) at high CV risk who are not adequately controlled with rosuvastatin (10mg or 20mg) with or witho...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001909-10 Sponsor Protocol Number: rosuva 10 Start Date*: 2005-02-02
    Sponsor Name:University of Dundee
    Full Title: Effect of Rosuvastatin on surrogate markers for cardiovascular events and joint disease progression in patients with rheumatoid arthritis
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002387-32 Sponsor Protocol Number: UoL001019 Start Date*: 2014-08-05
    Sponsor Name:University of Liverpool
    Full Title: Phase IIa, Randomised, Controlled, Open-Label Trial of Rosuvastatin for the Prevention of Aminoglycoside-Induced Kidney Toxicity in Children with Cystic Fibrosis
    Medical condition: Aminoglycoside-induced nephrotoxicity
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    18.0 10022891 - Investigations 10069022 Kidney injury molecule-1 PT
    18.0 100000004857 10067571 Nephrotoxicity LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004953-14 Sponsor Protocol Number: 0653-139 Start Date*: 2009-01-16
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Titration Study to Evaluate and Compare the Efficacy and Safety of Ezetimibe 10 mg Added on to Rosuvastatin 5 mg, 10 mg, 20 mg, or 40 mg Versus Up-Titration...
    Medical condition: hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020604 Hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-016492-29 Sponsor Protocol Number: D3561C00002 Start Date*: 2010-03-08
    Sponsor Name:AstraZeneca AB
    Full Title: An Efficacy and 2-Year Safety Study of Open-label Rosuvastatin in Children and Adolescents (aged from 6 to less than 18 years) with Familial Hypercholesterolaemia
    Medical condition: Male and female children and adolescents (aged 6 to < 18 years) with FH* and at least 1 of the following criteria: 1. Fasting LDL-C>190 mg/dL (4.92 mmol/L) at baseline OR 2. Fasting LDL-C >160 ...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-002889-11 Sponsor Protocol Number: D3560C00071 Start Date*: 2005-11-04
    Sponsor Name:AstraZeneca AB
    Full Title: An 18-Week, Randomized, Multicenter, Phase IIIb, Double-Blind, Crossover Study, Followed by an 18-Week Open-Label Period to Evaluate the Efficacy and Safety of the Lipid-Regulating Agents, Rosuvast...
    Medical condition: Dysbetalipoproteinemia (Fredrickson Type III Hyperlipoproteinemia)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2007-004894-25 Sponsor Protocol Number: ATCC10AA_IS_ICDJ10-J18 Start Date*: 2009-06-30
    Sponsor Name:Karolinska University Hospital Huddinge
    Full Title: Effect of rosuvastatin on cardiovascular events and mortality after pneumonia
    Medical condition: Community aquired pneumonia
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004762-40 Sponsor Protocol Number: Rosudip01 Start Date*: 2007-10-18
    Sponsor Name:Dept. Pharmacology and Toxicology
    Full Title: Rosuvastatin augments dipyridamole induced vasodilation by increased adenosine receptor stimulation
    Medical condition: Ischemia-reperfusion injury
    Disease: Version SOC Term Classification Code Term Level
    9.1 10023034 Ischemia peripheral LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004000-13 Sponsor Protocol Number: D356IC00001 Start Date*: 2008-02-07
    Sponsor Name:AstraZeneca AB
    Full Title: Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN (SATURN): A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comp...
    Medical condition: Coronary Atheroma -- The current trial will study patients who have a clinical indication for coronary catheterization and who have coronary artery disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) IT (Completed) BE (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-001860-22 Sponsor Protocol Number: CRT Start Date*: 2007-06-04
    Sponsor Name:Karl Andersen
    Full Title: CREATE. Cardiovascular Risk Evaluation and Attenuation of inflammation by early rosuvastatin TrEatment
    Medical condition: Patients with chest pain at rest or minimal physical activity of at least 20 minutes duration will be considered for inclusion in this study. To be eligible, patients have to be considered of low...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014364-18 Sponsor Protocol Number: 579/09 Start Date*: 2009-10-01
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: PSORIASIS AND CARDIOVASCULAR DISEASE: IMMUNOMODULATOR ROLE OF THE TREATMENT WITH ROSUVASTATIN IN PATIENTS WITH PSORIASIS OF MILD OR OF MODERATE-SEVERE SKIN DISEASE.
    Medical condition: PSORIASIS
    Disease: Version SOC Term Classification Code Term Level
    12.0 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003837-13 Sponsor Protocol Number: ROPPET-NAF Start Date*: 2020-04-20
    Sponsor Name:Centro Hospitalar e Universitário de Coimbra, E.P.E.
    Full Title: Rosuvastatin effect on atherosclerotic plaque metabolism ¿ a subclinical atherosclerosis imaging study with 18F-NaF PET-CT
    Medical condition: Atherosclerosis, namely in the aorta, carotid and coronary arteries
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002810-20 Sponsor Protocol Number: D356FC00003 Start Date*: 2007-09-13
    Sponsor Name:AstraZeneca AB
    Full Title: A 12-week Open-Label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to compare the Efficacy and Safety of rosuvastatin (CRESTOR) 10 mg and 20 mg in Combination with Ezetimibe 10 mg and ...
    Medical condition: Dyslipidemia - Expert groups have identified low-density lipoprotein cholesterol (LDL-C) as the primary target for cholesterol lowering therapy because it is strongly associated with coronary heart...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001559-15 Sponsor Protocol Number: CTO#2095 Start Date*: 2022-11-11
    Sponsor Name:Ottawa Hospital Research Institute
    Full Title: StAtins for Venous Event Reduction in Patients with Venous Thromboembolism
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002510-38 Sponsor Protocol Number: D3569C00007 Start Date*: 2005-12-19
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, 52-Week, Parallel-Group, Multicentre, Phase IIb Study to Evaluate the Effects of Rosuvastatin 10 mg, Rosuvastatin 40 mg and Atorvastatin 80 mg on Urinary Protein Excreti...
    Medical condition: Male and female patients aged >= 18 and <=70 years with Type 1 or 2 diabetes, moderate proteinuria (baseline urinary protein/creatinine ratio >=500 mg/g and <=5000 mg/g), mild hypercholesterolaemia...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004094-28 Sponsor Protocol Number: D3560L00030 Start Date*: 2005-05-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase III Study of Rosuvastatin (CRESTOR) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL...
    Medical condition: healthy subjects without prior history of MI, stroke or arterial revascularization who, on initial screening, are found to have LDL.C levels below 130 mg/dL (3.36 mmol/L) and CRP levels equal to or...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended) DE (Prematurely Ended) GB (Completed) EE (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015247-16 Sponsor Protocol Number: 162 Start Date*: 2010-10-11
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients with Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled with Atorvastatin 10 mg...
    Medical condition: Primary Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) FR (Completed) ES (Completed) FI (Completed) PT (Completed) DE (Completed) DK (Completed) SE (Completed) LT (Completed) EE (Completed) SI (Completed) SK (Completed) NL (Completed) CZ (Completed) BG (Completed) IT (Completed) HU (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2005-002508-41 Sponsor Protocol Number: D3569C00011 Start Date*: 2005-12-15
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, 52-week, Parallel-Group, Multicentre, Phase IIb Study to Evaluate the Effects of Rosuvastatin 10 mg, Rosuvastatin 40 mg and Atorvastatin 80 mg on Urinary Protein Excreti...
    Medical condition: Male and female, non-diabetic patients aged ≥18 with moderate proteinuria (baseline urinary protein/creatinine ratio ≥500 mg/g and ≤5000 mg/g), hypercholesterolaemia (fasting LDL-C ≥90 mg/dL (2.33 ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:57:06 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA